These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35415873)

  • 1. Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).
    Tanaka H; Sakamoto H; Akita T; Ohyanagi F; Kawashima Y; Tambo Y; Tanimoto A; Horiike A; Miyauchi E; Tsuchiya-Kawano Y; Yanagitani N; Nishio M
    Thorac Cancer; 2022 May; 13(10):1471-1478. PubMed ID: 35415873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
    Lavacchi D; Mazzoni F; Giaccone G
    Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
    Nagano T; Tachihara M; Nishimura Y
    Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
    Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
    Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Lee M; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Wu YL
    J Clin Oncol; 2018 Aug; 36(22):2244-2250. PubMed ID: 29864379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
    Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jänne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L
    Ann Oncol; 2016 Mar; 27(3):423-9. PubMed ID: 26768165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.
    Li HS; Zhang JY; Yan X; Xu HY; Hao XZ; Xing PY; Wang Y
    Cancer Med; 2022 Feb; 11(4):1026-1036. PubMed ID: 35023313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.
    Cheng WC; Lin CC; Liao WC; Lin YC; Chen CH; Chen HJ; Tu CY; Hsia TC
    BMC Cancer; 2024 Feb; 24(1):228. PubMed ID: 38373960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
    Cheng Y; Mok TS; Zhou X; Lu S; Zhou Q; Zhou J; Du Y; Yu P; Liu X; Hu C; Lu Y; Zhang Y; Lee KH; Nakagawa K; Linke R; Wong CH; Tang Y; Zhu F; Wilner KD; Wu YL
    Lung Cancer; 2021 Apr; 154():176-185. PubMed ID: 33721611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
    Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
    Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.
    Yamada Y; Imai H; Sugiyama T; Minemura H; Kanazawa K; Kasai T; Minato K; Kaira K; Kaburagi T
    Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577852
    [No Abstract]   [Full Text] [Related]  

  • 13. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
    Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Chawla A; Rosell R; Corral J; Migliorino MR; Pluzanski A; Noonan K; Tang Y; Pastel M; Wilner KD; Wu YL
    Drugs; 2021 Feb; 81(2):257-266. PubMed ID: 33331989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
    Peng W; Pu X; Jiang M; Wang J; Li J; Li K; Xu Y; Xu F; Chen B; Wang Q; Cao J; Chen Y; Wu L
    Lung Cancer; 2021 Feb; 152():66-70. PubMed ID: 33352385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases.
    Zhang J; Wang Y; Liu Z; Wang L; Yao Y; Liu Y; Hao XZ; Wang J; Xing P; Li J
    Thorac Cancer; 2021 Dec; 12(24):3407-3415. PubMed ID: 34751504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.
    Pu X; Zhou Y; Kong Y; Chen B; Yang A; Li J; Li K; Xu Y; Wu L
    BMC Cancer; 2023 Oct; 23(1):982. PubMed ID: 37840124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.